期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

茴拉西坦治疗帕金森痴呆的临床观察 被引量：3

暂未订购
导出
摘要 【目的】探讨茴拉西坦治疗帕金森痴呆的疗效和安全性。【方法】将诊断为轻至中度的帕金森病痴呆患者48例分为对照组和治疗组,在服用多巴丝肼的基础上,治疗组予300mg茴拉西坦每日三次,共12周治疗,治疗开始、第12周和24周分别进行简易智能状态检查量表(MMSE)及帕金森统一评分量表(UPDRS-partⅠ)检查,并记录治疗过程中出现的不良反应。【结果】治疗结束后及治疗后24周,治疗组MMSE总分较治疗前及对照组高(P<0.01),UPDRS得分两组间治疗前后无差异。【结论】茴拉西坦可改善帕金森患者的轻至中度痴呆,不良反应小,适于临床应用。
作者 李啬夫 丁玲
机构地区 湖南省长沙市三医院神经内科
出处 《医学临床研究》 CAS 2008年第1期141-142,共2页 Journal of Clinical Research
关键词 痴呆/病因学 帕金森病/并发症 痴呆/药物疗法 吡咯烷酮类/治疗应用
分类号 R749.160.25 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献9

  • 1王新德.帕金森病及帕金森综合征的诊断标准和鉴别诊断[J].中华神经精神科杂志,1985,18(4):256-256.
  • 2Emre M. Dementia associated with Parkinson's disease[J]. Lancet Neurol,2003, 2(4):229-237.
  • 3McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies[J]. Lancet Neurol ,2004,3(1): 19-28.
  • 4Aarsland D, Larsen JP, Karlsen K, et al . Mental symptoms in Parkinson's disease are important contributions to caregiver distress[J]. Int J Geriatr Psychiatry , 1999, 14 (10) :866- 874.
  • 5Huber SJ, Paulson GW, Shuttleworth EG. Relationship of motor symptoms, ntellectual impairment, and depression in Parkinson's disease[J]. J Neurol Neurosurg Psychiatry , 1988,51 (6) :855-858.
  • 6谭玉燕,陈生弟.帕金森病痴呆的临床特征及治疗进展[J].中华神经科杂志,2006,39(6):413-415. 被引量：19
  • 7Junque C, Ramrez-Ruiz B, Tolosa E, et al . Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia[J]. Mov Disord ,2005,20(5):540-544.
  • 8金永寿.新促智药茴拉西坦(Aniracetam)[J].国外医药（合成药．生化药．制剂分册）,1994,15(6):337-340. 被引量：12
  • 9孙宜萍,潘士荣,马晓园,孙洁.茴拉西坦对记忆减退的疗效[J].新药与临床,1993,12(2):74-76. 被引量：5

二级参考文献12

  • 1Aarsland D,Andersen K,Larsen JP,et al.Prevalence and characteristics of dementia in Parkinson disease:an 8-year prospective study.Arch Neurol,2003,60:387-392.
  • 2Aarsland D,Zaccai J,Brayne C.A systematic review of prevalence studies of dementia in Parkinson's disease.Mov Disord,2005,20:1255-1263.
  • 3Junque C,Ramrez-Ruiz B,Tolosa E,et al.Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia.Mov Disord,2005,20:540-544.
  • 4Camicioli R,Moore MM,Kinney A,et al.Parkinson's disease is associated with hippocampal atrophy.Mov Disord,2003,18:784-790.
  • 5Kovari E,Gold G,Herrmann FR,et al.Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease.Acta Neuropathol (Berl),2003,106:83 -88.
  • 6Papapetropoulos S,Lieberman A,Gonzalezl J,et al.Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease.Acta Neurol Scand,2005,111:353-359.
  • 7McKeith I,Mintzer J,Aarsland D,et al.Dementia with Lewy bodies.Lancet Neurol,2004,3:19-28.
  • 8Collerton D,Burn D,McKeith I.Systematic review and metaanalysis show that dementia with Lewy bodies is a visual perceptual and attentional-executive dementia.Dement Geriatr Cogn Disord,2003,16:229-237.
  • 9Boeve F,Silber M,Ferman T.REM Sleep Behavior Disorder in Parkinson's Disease and Dementia With Lewy Bodies.J Geriatr Psychiatry Neurol,2004,17:146-157.
  • 10Emre M,Aarsland D,Albanese A,et al.Rivastigmine for dementia associated with Parkinson's disease.N Engl J Med,2004,351:2509-2518.

共引文献153

同被引文献30

  • 1张春艳,刘海丽.尼麦角林治疗血管性帕金森综合征30例临床分析[J].中国医药,2006,1(4):253-253. 被引量：3
  • 2谭玉燕,陈生弟.帕金森病痴呆的临床特征及治疗进展[J].中华神经科杂志,2006,39(6):413-415. 被引量：19
  • 3于兑声,恽晓平.运动疗法与作业疗法[M].北京:华夏出版社,2002:472-474,480-481.
  • 4Aaraland D,Andersen K,Larsen JP,et al. Prevalence and characteristicsof dementia in Parkinson disease : an 8 -year prospective study [ J〕. ArchNeural,2003;60(3) :387-92.
  • 5American Psychiatric Association. Diagnostic and statistical manual ofmental disorders DSM-IV [ M] . Washington DC: American PsychiatricAssociation, 2000 ; 78.
  • 6McKeith I,Mintzer J, Aarsland ,et al. Dementia with Lewy bodies〔 J〕.Lancet Neurol,2004;3(1): 19-28.
  • 7Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzhei-mere disease : tolerability and safety data from clinical trials (J ]. DrugSafety,2008;31(7) :577.
  • 8Sonkusare SK, Kanl CL, Ramarao P. Dementia of Alzherimerc' s diseaseand other neurodegenerative disorders-memantine,a new hope〔 J〕. Phar-macol Res,2005;51(l) :4-71.
  • 9Varanese S, Howard J, Dirocco A. NMD A antagonist memantine improveslevodopa-induced dyskinesis and“ on-off” phenomena in Parkinson^ dis-ease [J}. Movement Disorders,2010;25 (4) :508.
  • 10Aaraland D,Andersen K,Larsen JP. Prevalence and characteristicsof dementia in Parkinson disease:an 8-year prospective study[J].Archives of Neurology,2003.387-392.

引证文献3

医学临床研究
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部